Medicamentsen-ligne vous propose les traitements dont vous avez besoin afin de prendre soin de votre santé sexuelle. Avec plus de 5 ans d'expérience et plus de 90.000 clients francophones, nous étions la première clinique fournissant du acheter cialis original en France à vente en ligne et le premier vendeur en ligne de Kamagra dans le monde. Pourquoi prendre des risques si vous pouvez être sûr avec Medicamentsen-ligne - Le service auquel vous pouvez faire confiance.

Microsoft word - rrv nsc cv.doc

CURRICULUM VITAE
Rafael A. Rivas-Vazquez, Psy.D.

Office Address NeuroScience

Home Address 749

Date of Birth January

Place of Birth Miami,

Education
Master’s of Science in Clinical Psychopharmacology
Pre-doctoral and Post-doctoral Training
Harvard Medical School/Massachusetts General Hospital
Licensure
Florida Board of Psychology, License #PY0004519
Board Certification
American Board of Professional Psychology Diplomate in Clinical Psychology, Certificate #5039
Board Appointments
CURRICULUM VITAE
Rafael A. Rivas-Vazquez, Psy.D.

Academic Appointments
Clinical Fellow in the Department of Psychiatry Instructor in the Department of Psychiatry Voluntary Assistant Professor in the Department of Neurology Adjunct Associate Professor in the Department of Psychology
Staff Appointments
Massachusetts General Hospital, Boston, MA New England Memorial Hospital, Stoneham, MA
Professional Experience
Coordinator of Inpatient Training for Pre-doctoral Internship Massachusetts General Hospital, Boston, MA Massachusetts General Hospital, Boston, MA Director, Mobile Crisis Services for Hurricane Andrew Relief Effort Director, Assessment and Emergency Service AuroraCare Behavioral Managed Care Company, Miami, FL Baptist Memory Disorders Center, Miami, FL CURRICULUM VITAE
Rafael A. Rivas-Vazquez, Psy.D.

Committee Assignments
South Florida Interprofessional Council Representative Psychopharmacology Committee, Chairperson PsychStar Behavioral Managed Care Company Alzheimer’s Association of Greater Miami Quality Improvement Committee, Chairperson
Memberships in Professional Associations
International Neuropsychological Society
Original Reports
Rivas-Vazquez, R., & Blais, M. (1997). Selective serotonin reuptake inhibitors and atypical antidepressants: A review and update for psychologists. Professional Psychology: Research and Practice, 28, 526–536. Carrazana, E., DeToledo, J., Tatum, W., Wheeler, S., & Rivas-Vazquez, R. (1999). Epilepsy and religious experiences: Voodoo possession. Epilepsia, 40, 239–241. Rivas-Vazquez, R., Johnson S.L., Blais, M., & Rey, G. (1999). Selective serotonin reuptake inhibitor discontinuation syndrome: Understanding, recognition and management for psychologists. Professional Psychology: Research and Practice, 30, 464–469. Rey, G.J., Feldman, E., Rivas-Vazquez, R., Levin, B.E., & Benton, A.L. (1999). Neuropsychological test development and normative data on Hispanics. Archives of Clinical Neuropsychology, 14, 593–601. CURRICULUM VITAE
Rafael A. Rivas-Vazquez, Psy.D.

Rivas-Vazquez, R., Blais, M.A., Rey, G.J., & Rivas-Vazquez, A. (2000). Atypical antipsychotics: Pharmacologic profiles and psychologic implications. Professional Psychology: Research and Practice, 31, 628–640. Rivas-Vazquez, R., Carrazana, E.J., Rey, G.J., Blais, M.A., & Racher, D.A. (2000). Alzheimer’s disease: Pharmacologic treatment and management. The Clinical Neuropsychologist, 14, 93–109. Rivas-Vazquez, R., Rivas-Vazquez A, Rey, G.J., & Blais, M.A. (2000). Sexual dysfunction associated with antidepressant treatment. Professional Psychology: Research and Practice, 31, 641–651. Rivas-Vazquez, R., Carrazana, E.J., Rey, G.J., & Wheeler, S.D. (2000). Selective serotonin reuptake inhibitor discontinuation syndrome: Three cases presenting to a neurologic practice. The Neurologist, 6, 348–352. 9) Rivas-Vazquez, R. (2001). Antidepressants as first-line agents in the current pharmacotherapy of anxiety disorders. Professional Psychology: Research and Practice, 32, 101–104. 10) Carrazana, E., Rey, G., Rivas-Vazquez, R., & Tatum, W. (2001). Ictal “alien” hand syndrome. Epilepsy and Behavior, 2, 61–64. 11) Rivas-Vazquez, R., Blais, M., Rey, G., & Rivas-Vazquez, A. (2001). A brief reminder about documenting the psychological consultation. Professional Psychology: Research and Practice, 32, 194–199. 12) Rivas-Vazquez, R. (2001). Reboxetine: Refocusing on the role of norepinephrine in the treatment of depression. Professional Psychology: Research and Practice, 32, 211–214. 13) Rey, G.J., Feldman, E., Hernandez, D., Levin, B.E., Rivas-Vazquez, R., LeBlanc, W.G., & Benton, A.L. (2001). Application of the Multilingual Aphasia Examination - Spanish in the evaluation of Hispanic patients post-traumatic brain injury. The Clinical Neuropsychologist, 15, 13–18. 14) Rivas-Vazquez, R. (2001). St. John’s wort (Hypericum perforatum): Practical considerations based on the evidence. Professional Psychology: Research and Practice, 32, 329–332. 15) Carrazana, E.J., Rivas-Vazquez, R., Rey J, & Rey, G.J. (2001). SSRI discontinuation syndrome exacerbated by buspirone (letter). American Journal of Psychiatry, 158, 966–967. 16) Rivas-Vazquez, R. (2001). Cholinesterase inhibitors: Current pharmacological treatments for Alzheimer's disease. Professional Psychology: Research and Practice, 32, 433–436. 17) Blais, M., Rivas-Vazquez, R., Rey, G.J., Racher, D.A., & Carrazana, E.J. (2001). Treatment and management of Alzheimer's disease. Clinical Geriatrics, 9, 58–65. 18) Rivas-Vazquez, R. (2001). Understanding drug interactions. Professional Psychology: Research and Practice, 32, 543–547. 19) Rivas-Vazquez, R., Rivas-Vazquez, A., Blais, M., Rey, G.J., Rivas-Vasquez, F., Jacobo, M., & Carrazana, E.J. (2001). Development of a Spanish version of the Schwartz Outcome Scale - 10: A brief mental health outcome measure. Journal of Personality Assessment, 77, 436–446. CURRICULUM VITAE
Rafael A. Rivas-Vazquez, Psy.D.

20) Rivas-Vazquez, R. (2001). Ziprasidone: Pharmacological and clinical profile of the newest atypical antipsychotic. Professional Psychology: Research and Practice, 32, 662–665. 21) Rivas-Vazquez, R., & Blais, M. (2002). Pharmacologic treatment of personality disorders. Professional Psychology: Research and Practice, 33, 101–104. 22) Rivas-Vazquez, R., Johnson, S.L., Rey, G.J., & Blais, M. (2002). Current treatments for bipolar disorder: A review and update for psychologists. Professional Psychology: Research and Practice, 33, 212–223. 23) Rivas-Vazquez, R., & Rey, J. (2002). Weight gain and metabolic disturbances associated with the atypical antipsychotics. Professional Psychology: Research and Practice, 33, 341–344. 24) Rivas-Vazquez, R., & Delgado, L. (2002). Clinical and toxic effects of MDMA (“Ecstasy”). Professional Psychology: Research and Practice, 33, 422–425. 25) Rivas-Vazquez, R., & Mendez, C.I. (2002). Overview of the drug approval process. Professional Psychology: Research and Practice, 33, 502–506. 26) Blais, M.A., Matthews, J., Lipkis-Orlando, R., O’Keefe, S.M., Jacobo, M., Rivas- Vazquez, R.A, & Summergrad, P. (2002). Development and application of a multi-faceted tool for evaluating inpatient psychiatric care. Administration and Policy in Mental Health, 30, 159–172. 27) Rivas-Vazquez, R.A. (2003). Aripiprazole: A novel antipsychotic with dopamine stabilizing properties. Professional Psychology: Research and Practice, 34, 108–111. 28) Rivas-Vazquez, R.A., & Perel, J.M. (2003). The role of stereochemistry and chiral pharmacology in psychotropic drug development. Professional Psychology: Research and Practice, 34, 210–213. 29) Rivas-Vazquez, R.A. (2003). Benzodiazepines in contemporary clinical practice. Professional Psychology: Research and Practice, 34, 324–328. 30) Feldman, L.B., & Rivas-Vazquez, R.A. (2003). Assessment and treatment of social anxiety disorder. Professional Psychology: Research and Practice, 34, 396–405. 31) Rivas-Vazquez, R.A, & Resnick, M. (2003). The emerging role of glutamate in the pathophysiology and treatment of psychiatric disorders. Professional Psychology: Research and Practice, 34, 444–448. 32) Rivas-Vazquez, R.A, Rice, J., & Kalman, D. (2003). Pharmacotherapy of obesity and eating disorders. Professional Psychology: Research and Practice, 34, 562–566. 33) Rivas-Vazquez, R.A. (2003). Atomoxetine: A selective norepinephrine reuptake inhibitor for the treatment of Attention-Deficit/Hyperactivity Disorder. Professional Psychology: Research and Practice, 34, 666–669. 34) Rivas-Vazquez, R.A, Mendez, C., Rey, G.J., & Carrazana, E.J. (2004). Mild cognitive impairment: New neuropsychological and pharmacological target. Archives of Clinical Neuropsychology, 19, 11–27. 35) Rivas-Vazquez, R.A, Saffa-Biller, D., Ruiz, I., Blais, M.A., & Rivas-Vazquez, A. (2004). Current issues in anxiety and depression: Comorbid, mixed and subthreshold disorders. Professional Psychology: Research and Practice, 35, 74–83. CURRICULUM VITAE
Rafael A. Rivas-Vazquez, Psy.D.

36) Rivas-Vazquez, R.A., Sarria, M., Rey, G., Rivas-Vazquez, A., Rodriguez, J. & Jardon, M. (2009). A relationship-based care model for jail diversion. Psychiatric Services, 60, 766–771. 37) Rivas-Vazquez, R.A., Bello, I., Sarria, M., Fernandez, N., & Rey, G.J. (2011). Prevalence of Metabolic Syndrome in a Predominantly Cuban, Psychiatrically Ill and Homeless Population. Primary Care Companion for CNS Disorders, 13(3), e1–e5. 38) Rey, G.J., Rivas-Vazquez, R., Garaycoa, G., Mendez, C., Bello, I., & Carrazana, E.J. (in press). A prospective study monitoring AD patients during a switch from donepezil to rivastigmine. The Neurologist. 39) Blais, M.A., Blagys, M.D., Lechner, E., Rivas-Vazquez, R., Martinez-Arrue, R., Orlandini, E., & Bello, I. (in press). Development and initial validation of an ultra-brief measure of psychiatric symptom distress. Journal of Personality Assessment. 40) Rey, G.J., Schatz, N., Bauerlain, E.J., Bowen, B., Rivas-Vazquez, R., & Carrazana, E.J. (under review). Transient Balint's syndrome following heart transplantation. Neuro-ophthalmology.
Book Chapters
Blais, M., Smallwood, P., Groves, J., & Rivas-Vazquez R. Personality and Personality Disorders. In T. Sterns, J. Rosenbaum, M. Fava, J. Biedermen & S. Rauch (Ed.) Handbook of Comprehensive Clinical Psychiatry (2008, pp. 527-542).
Abstracts
Rivas-Vazquez, A., & Rivas-Vazquez, R. (1986, May). Family restructuring: An alternative to teen suicide. Presented at the American Association of Suicidology Conference, Atlanta, Georgia. Rey, G.J., Feldman, E., Rivas-Vazquez, R., & Benton, A.L. (1994, August). Current trends and future of neuropsychological research with Hispanics. Presented at the annual meeting of the American Psychological Association, Los Angeles, California. Rey, G.J., Levin, B.E., Brown, M.C., Feldman, E., Rivas-Vazquez, R., Arias, M., & Benton, A.L. (1995). Application of the Benton tests to Hispanic adults: A preliminary analysis. Journal of the International Neuropsychological Society, 1. Carrazana, E., DeToledo, J., Tatum, W., Rivas-Vazquez, R., Rey, G., Wheeler, S., & Ramirez-Mejia, C. (1998, December). Epilepsy and religious experiences: Voodoo possession. Presented at the annual meeting of the American Epilepsy Society, San Diego, California. Carrazana, E., DeToledo, J., Tatum, W., Rivas-Vazquez, R., Rey, G., Wheeler, S., & Ramirez-Mejia, C. (1998, December). Erroneous attribution of epileptic seizures to voodoo spirit possession. Presented at the troisieme Congres de Neurologie Tropicale, Martinique. 6) Rivas-Vazquez, R., Carrazana, E.J., Rey, G.J., & Mendoza, R. (1999, January). Clinical and psychosocial characteristics of Caribbean and Anglo-Saxon dementia referrals in South Florida. Presented at the tenth annual meeting of the American Neuropsychiatric Association, New Orleans, Louisiana. CURRICULUM VITAE
Rafael A. Rivas-Vazquez, Psy.D.

Rey, G.J., Rivas-Vazquez, R., Feldman, E., & Carrazana, E.J. (1999, January). The evaluation of “executive” functions in Hispanics. Presented at the tenth annual meeting of the American Neuropsychiatric Association, New Orleans, Louisiana. Carrazana, E.J., Wheeler, S., Aptman, M., Zwibel, H., Kobetz, S., Racher, D., Grant, T., Faradji, V., Ramirez-Mejia, C., Rivas-Vazquez, R., & Rey, G.J. (1999, December). Second generation anticonvulsants utilization in clinical neurology (abstract #10022). Presented at the annual meeting of the American Epilepsy Society, Orlando, Florida. Rivas-Vazquez, R., Rey, G.J., Blais, M.A., Carrazana, E.J., & Schwartz, H. (2000, June). Development and validation of the Spanish version of the Schwartz Outcome Scale - 10. Presented at the 40th annual New Clinical Drug Evaluation Unit meeting, Boca Raton, Florida. 10) Rey, G.J., Rivas-Vazquez, R., Carrazana, E.J., Mendoza, R., Garaycoa, G., & Schwartz, H. (2000, June). Cross-cultural comparisons of dementia referrals in South Florida: Clinical and psychosocial factors. Presented at the 40th annual New Clinical Drug Evaluation Unit meeting, Boca Raton, Florida. 11) Carrazana, E.J., Espinosa, I., Wheeler, S., Espinosa, J., Rey, G.J., Rivas-Vazquez, R., & Ramirez-Mejia, C. (2000, December). Is folic acid for reduction of anticonvulsants’ teratogenic risk part of the standard neuropsychiatric clinical practice? Results of a survey. Presented at the annual meeting of the American Epilepsy Society, Los Angeles, California. 12) Rey, G.J., Carrazana, E.J., Garaycoa, G., Rivas-Vazquez, R., Espinosa, I., & Ramirez- Mejia, C. (2000, December). Affective disorders in juvenile myoclonic epilepsy: A prospective study. Presented at the annual meeting of the American Epilepsy Society, Los Angeles, California. 13) Johnson, S.L., Rugerro, C., Winters, R., Gotlib, I.H., Ahmed, Z., & Rivas-Vazquez, R. (2001, July). The behavioral activation system and mania: Cognitive-behavioral implications. Presented at the annual meeting of the World Congress of Behavioral and Cognitive Therapies, Vancouver, British Columbia. 14) Blagys, M.D., Blais, M.A., Lechner, E., Rivas-Vazquez, R., Martinez-Arrue, R., Orlandini, E., & Bello, I. (2002, March). Initial development of an ultra-brief measure of psychiatric symptoms distress: The AT-25. Presented at the midwinter meeting of the Society for Personality Assessment meeting, San Antonio, Texas 15) Miller, D., Gonzalez, E., Rivas-Vazquez, R., & Blais, M.A. (2002, March). The Word Association Test (WAT): A predictor of suicide? Presented at the midwinter meeting of the Society for Personality Assessment meeting, San Antonio, Texas 16) Rey, G.J., Garaycoa, G., Rivas-Vazquez, R., Bello, I., Campos, L., & Carrazana, E.J. (2002, May). Clinical and neuropsychological findings in patients with Alzheimer’s disease during switch from donepezil to rivastigmine. Presented at the annual meeting of the American Geriatrics Society, Washington, D.C. 17) Rey, G.J., Rivas-Vazquez, R., Mendoza, R., Garaycoa, G., & Carrazana, E. (2005, February). A Spanish verbal learning test: normative and clinical data. Presented at the 33rd annual International Neuropsychological Society meeting, San Louis, Missouri. CURRICULUM VITAE
Rafael A. Rivas-Vazquez, Psy.D.

18) Rey, G.J., Mendez, C., Rivas-Vazquez, R., & Bello, I. (2005, February). Neuro- psychiatric symptomatology and caregiver distress in Alzheimer’s Disease: A comparison of Hispanic and Anglosaxon groups. Presented at the 33rd annual International Neuropsychological Society meeting, San Louis, Missouri. 19) Sarria, M., Rivas-Vazquez, R.A., & Martinez, H. (2008, March). Relationship-based care effects on jail diversion. Presented at the 2008 CMHS National GAINS Center Conference, Washington, D.C.
Other Publications
Rivas-Vazquez, R. (1990). Assessing differential levels of affective expression in bilingual subjects using the Thematic Apperception Test. Unpublished doctoral dissertation. Nova Southeastern University, Florida. 2) Rivas-Vazquez, R., & Samek, W.R. (1996). Update on prescription privileges. Florida Psychologist, 47, 26–27. Carrazana, E.J., & Rivas-Vazquez, R. (1999). Antiepileptic drugs in the management of mood disorders. Monograph supported by unrestricted grant from Parke-Davis/Warner Lambert. Rivas-Vazquez, R., Johnson, S.L., Blais, M., & Rey, G. (2000). Recognizing SSRI discontinuation syndrome. Clinician’s Research Digest, 18, 3.
Lectures and Presentations
Effects of language on assessment and treatment of Hispanic patients. Presented at Massachusetts General Hospital/Chelsea Mental Health Center Teaching Rounds, May 1991, Boston, Massachusetts. Introduction to DSM-IV. Presented at Northwest Dade Mental Health Center Grand Rounds, August 1994, Hialeah, Florida. Clinical best practices in Medicaid managed care. Presented at Public/Private Regional Symposia: Integrating Public and Private Funding Streams and Delivery Systems in Behavioral Health Care, October 1996, Clearwater Beach, Florida. An update on Medicaid managed care in Florida. Presented at Linking Forces VI: The Sixth Annual Children's Mental Health Conference, May 1997, Miami, Florida. Overview of Alzheimer's disease. Presented at The Alzheimer's Association Fifth Annual Educational Forum, November 1997, Miami, Florida. 6) Alzheimer's management and treatment issues. Sponsored by the Puerto Rican Neurophysiology Society and Pfizer-Eisai Pharmaceutical Companies. May 1998, San Juan, Puerto Rico. Dementia ‘99: An update in diagnosis, treatment and reimbursement. Sponsored by Novartis Pharmaceuticals Corporation. February 1999, Boca Raton, Florida. Psychological aspects of headaches. Presented at the Baptist Hospital Symposium for migraine management May 1999, Miami, Florida. Impact of psychosocial stress on diabetes control. Presented at the Diabetes 2000: Management strategies for the new millennium. Sponsored by the Diabetes Care Centers of Baptist Health Systems. July 1999, Barcelona, Spain. CURRICULUM VITAE
Rafael A. Rivas-Vazquez, Psy.D.

10) Cognitive issues associated with the use of antipsychotics in elderly patients. Presented at the Novartis Advisory Board Meeting: Psychosis in the elderly patient. February 2002, New Orleans, Louisiana. 11) Baker act: Responsibilities and risks under the law. Presented at the South Florida Hospital and Healthcare Association Meeting, November 2008, Weston, Florida.
Pharmaceutical Associations
Parke-Davis, Warner Lambert Pharmaceutical Speakers Bureau Novartis Pharmaceuticals Corporation National Speakers Bureau
Research Experience
Principal Investigator, Berlex Laboratories: Multiple Sclerosis, June 1995 Bristol Myers Squibb: Generalized Anxiety Disorder, June 1997 Pharmaceuticals: Alzheimer's Disease, September 1997 Sub-investigator, Takeda: Alzheimer's Disease, March 1998 Bristol-Myers Squibb: Generalized Anxiety Disorder, April 1998 & Co., Inc.: Major Depressive Disorder, April 1998 Principal Investigator, SmithKline Beecham: Generalized Anxiety Disorder, December 1998 10) Principal Investigator, SmithKline Beecham: Posttraumatic Stress Disorder, February 11) Sub-investigator, Eisai: Dementia Associated with Cerebrovascular Disease, February 12) Sub-investigator, Medeva Development: Pediatric Attention Deficit Hyperactivity 13) Sub-investigator, Bristol-Myers Squibb: Pediatric Generalized Anxiety Disorder, July Bristol-Myers Squibb: Major Depressive Disorder, July 1999 Neo-Therapeutics: Alzheimer's Disease, September 1999 16) Sub-investigator, SmithKline Beecham: Premenstrual Dysphoric Disorder, September 17) Sub-investigator, Eisai: Dementia Associated with Cerebrovascular Disease, October 18) Sub-investigator, Novartis: Mild Cognitive Impairment, December 1999 19) Sub-investigator, Tap Holdings, Inc.: Major Depressive Disorder, January 2000 20) Principal 21) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder, March 23) Sub-investigator, Eli Lilly: Generalized Anxiety Disorder, August 2000 CURRICULUM VITAE
Rafael A. Rivas-Vazquez, Psy.D.

24) Sub-investigator, Wyeth-Ayerst: Pediatric Generalized Anxiety Disorder, August 2000 25) Sub-investigator, Wyeth-Ayerst: Adolescent Social Anxiety Disorder, August 2000 26) Sub-investigator, Major Depressive Disorder, October 2000 27) Sub-investigator, Pfizer: Alzheimer's Disease, February 2001 28) Sub-investigator, Forest Laboratories: Generalized Anxiety Disorder, March 2001 29) Sub-investigator, Janssen: Alzheimer's Disease, March 2001 30) Sub-investigator, Laboratories: Moderate to Severe Alzheimer's Disease, April 31) Sub-investigator, SmithKline Beecham: Major Depressive Disorder with Anxiety, 32) Sub-investigator, Janssen: Mild Cognitive Impairment, April 2001 33) Sub-investigator, Wyeth-Ayerst: Panic Disorder, April 2001 Forest Laboratories: Generalized Anxiety Disorder, May 2001 35) Sub-investigator, Eli Lilly: Schizophrenia, September 2001 36) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder, 37) Sub-investigator, GlaxoSmithKline: Major Depressive Disorder, September 2001 38) Sub-investigator, Pfizer: Major Depressive Disorder with Somatic Symptoms, 39) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity Laboratories: Adult Attention Deficit Hyperactivity Disorder, 41) Sub-investigator, Novartis: Cerebrovascular Dementia, February 2002 42) Sub-investigator, Eli Lilly: Antipsychotic-induced weight gain, March 2002 43) Sub-investigator, Forest Laboratories: Mild to Moderate Alzheimer's Disease, April 44) Sub-investigator, Pharmacia Upjohn: Generalized Anxiety Disorder, April 2002 45) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder, July Major Depressive Disorder, October 2002 47) Sub-investigator, Eli Lilly: Fibromyalgia with or without depression, November 2002 48) Sub-investigator, Laboratories: Major Depressive Disorder, November 2002 Sanofi-Synthelabo: Smoking Cessation, November 2002 50) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity 51) Sub-investigator, Johnson & Johnson: Mild Cognitive Impairment, January 2003 52) Sub-investigator, Sanofi-Synthelabo: Alzheimer's Disease, June 2003 Sanofi-Synthelabo: Major Depressive Disorder, August 2003 55) Sub-investigator, Boehringer-Ingelheim: Parkinson's Disease, September 2003 56) Sub-investigator, 57) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder, CURRICULUM VITAE
Rafael A. Rivas-Vazquez, Psy.D.

Merck & Co., Inc.: Alzheimer's Disease, November 2003 59) Sub-investigator, Wyeth Research: Alzheimer's Disease, November 2003 60) Principal Investigator, Wyeth Research: Major Depressive Disorder, December 2003 61) Sub-investigator, Cephalon: Pediatric Attention Deficit Hyperactivity Disorder, 62) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder and 63) Principal Investigator, Wyeth Research: Major Depressive Disorder, January 2004 64) Sub-investigator, Sepracor: Insomnia related to Major Depressive Disorder, March Cephalon: Pediatric Attention Deficit Hyperactivity Disorder, May 66) Sub-investigator, GlaxoSmithKline: Parkinson's Disease, May 2004 67) Sub-investigator, Sanofi-Synthelabo: Fibromyalgia, June 2004 Laboratories: Adult Attention Deficit Hyperactivity Disorder, 70) Sub-investigator, Shire Laboratories: Adolescent Attention Deficit Hyperactivity 71) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity 72) Sub-investigator, Eli Lilly: Major Depressive Disorder, November 2004 73) Sub-investigator, Cephalon: Generalized Anxiety Disorder, November 2004 74) Sub-investigator, 75) Sub-investigator, Cephalon: Generalized Anxiety Disorder, January 2005 76) Sub-investigator, Novartis: Generalized Anxiety Disorder, March 2005 77) Sub-investigator, Sanofi-Synthelabo: Major Depressive Disorder, March 2005 Laboratories: Adult Attention Deficit Hyperactivity Disorder, 79) Sub-investigator, Cephalon: Narcolepsy in Children and Adolescents, June 2005 80) Sub-investigator, Cephalon: Obstructive Sleep Apnea in Children and Adolescents, 81) Sub-investigator, Eli Lilly: Fibromyalgia, July 2005 82) Sub-investigator, Cephalon: Excessive Sleepiness in Children and Adolescents, July 83) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity Laboratories: Adult Attention Deficit Hyperactivity Disorder, Sanofi-Synthelabo: Generalized Anxiety Disorder, December 2005 86) Sub-investigator, Pfizer/Neurocrine Biosciences: Insomnia and Major Depressive 87) Sub-investigator, Pfizer: Generalized Anxiety Disorder, November 2005 88) Principal Investigator, Wyeth Research: Major Depressive Disorder, February, 2006 CURRICULUM VITAE
Rafael A. Rivas-Vazquez, Psy.D.

89) Sub-investigator, Wyeth Research: Fibromyalgia, June 2006 90) Sub-investigator, New River Pharmaceuticals: Adult Attention Deficit Hyperactivity 91) Sub-investigator, Wyeth Research: Fibromyalgia (Open-label Extension), August 2006 92) Sub-investigator, New River Pharmaceuticals: Adult Attention Deficit Hyperactivity 93) Sub-investigator, INC Research: Mild Cognitive Impairment following Coronary 94) Sub-investigator, Novartis: Major Depressive Disorder, October 2006 95) Sub-investigator, Eisai: Parkinson's Disease, November 2006 96) Sub-investigator, Wyeth Research: Alzheimer's Disease, November 2006 97) Sub-investigator, Boehringer-Ingelheim: Parkinson's Disease, December 2006 98) Sub-investigator, Shire Development Inc: Pediatric Attention Deficit Hyperactivity Disorder with Oppositionality, January 2007 99) Sub-investigator, Eli Lilly: Adult Attention Deficit Hyperactivity Disorder, January 100) Sub-investigator, Shire Pharmaceutical Development Inc: Pediatric Attention Deficit 101) Sub-investigator, Eli Lilly: Chronic Lower Back Pain, January 2007 102) Principal Investigator, Wyeth Research: Major Depressive Disorder, March 2007 103) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity 104) Sub-investigator, Shire Laboratories: Adolescent Attention Deficit Hyperactivity 105) Sub-investigator, Eli Lilly: Pediatric Major Depressive Disorder, June 2007 106) Sub-investigator, Wyeth Research: Alzheimer's Disease, June 2007 107) Sub-investigator, Shire Laboratories: Adolescent Attention Deficit Hyperactivity 108) Sub-investigator, Abbott Laboratories: Adult Attention Deficit Hyperactivity Disorder, 109) Sub-investigator, Pfizer Inc: Generalized Anxiety Disorder, August 2007 110) Sub-investigator, Arena Pharmaceuticals, Obesity, January 2008 111) Sub-investigator, Novartis, Major Depressive Disorder, February 2008 112) Sub-investigator, Johnson and Johnson PRD, LLC: Adult Attention Deficit 113) Sub-investigator, Elan: Alzheimer's Disease, April 2008 114) Sub-investigator, Takeda: Major Depressive Disorder, April 2008 115) Sub-investigator, Pfizer Inc: Adults with Nonrestorative Sleep, April 2008 116) Sub-investigator, Sepracor: Pediatric Attention Deficit Hyperactivity Disorder with 117) Sub-investigator, Eli Lilly, Fibromyalgia, June 2008 118) Sub-investigator, Takeda: Generalized Anxiety Disorder, June 2008 119) Sub-investigator, Pfizer Inc: Generalized Anxiety Disorder, June 2008 120) Sub-investigator, Schering-Plough: Obesity, July 2008 CURRICULUM VITAE
Rafael A. Rivas-Vazquez, Psy.D.

121) Sub-investigator, Shire Laboratories, Adolescent Attention Deficit Hyperactivity 122) Sub-investigator, Novartis, Pediatric Attention Deficit Hyperactivity Disorder, October 123) Sub-investigator, Shire Laboratories, Pediatric Attention Deficit Hyperactivity Disorder 124) Sub-investigator, Pfizer Inc., Generalized Anxiety Disorder (Open-label Extension), 125) Sub-investigator, Pfizer Inc., Alzheimer's Disease, December 2008 126) Sub-investigator, Bristol-Myers Squibb, Alzheimer's Disease, December 2008 127) Sub-investigator, Johnson and Johnson PRD, LLC, Adult Attention Deficit 128) Sub-investigator, Eli Lilly, Osteoarthritis Knee Pain, March 2009 129) Sub-investigator, Neurogen Corporation, Restless Leg Syndrome, April 2009 130) Sub-investigator, Mylan Pharmaceuticals, Inc, Schizophrenia, June 2009 131) Principle Investigator, Wyeth Research, Major Depressive Disorder, June 2009 132) Sub-investigator, Shire Laboratories, Adult Attention Deficit Hyperactivity Disorder, 133) Sub-investigator, Eli Lilly, Pediatric Attention Deficit Hyperactivity Disorder, July 134) Principle Investigator, Wyeth Research, Major Depressive Disorder, July 2009 135) Sub-investigator, Pfizer Inc., Sleep Maintenance, July 2009 136) Sub-investigator, Eli Lilly, Pediatric Attention Deficit Hyperactivity Disorder (Open- 137) Sub-investigator, Cephalon, Mild to Moderate Closed Traumatic Brain Injury, October 138) Sub-investigator, Eli Lilly, Obesity, October 2009 139) Sub-investigator, Bristol-Myers Squibb, Alzheimer's Disease, October 2009 140) Sub-investigator, Elan, Alzheimer's Disease (Extension), December 2009 141) Sub-investigator, Pfizer, Restless Legs Syndrome, January 2010 142) Sub-investigator, Tibotec Pharmaceuticals, Hepatitis C, January 2010 143) Sub-investigator, Cephalon, Excessive Sleepiness Associated with Shift Work, March 144) Sub-investigator, Forest Laboratories, Major Depressive Disorder, March 2010 145) Sub-investigator, Otsuka, Adult Attention Deficit Hyperactivity Disorder, June 2010 146) Sub-investigator, Novartis, Major Depressive Disorder, July 2010 147) Sub-investigator, Novartis, Migraines, November 2010 148) Sub-investigator, Novartis, Pediatric Attention Deficit Hyperactivity Disorder, December 2010 149) Sub-investigator, Janssen, Alzheimer's Disease, January 2011 150) Sub-investigator, Eli Lilly, Migraines, March 2011 151) Sub-investigator, AstraZeneca, Major Depressive Disorder, May 2011 152) Sub-investigator, Abbott, Major Depressive Disorder, June 2011 CURRICULUM VITAE
Rafael A. Rivas-Vazquez, Psy.D.

153) Sub-investigator, Shire Laboratories, Adolescent Attention Deficit Hyperactivity 154) Sub-investigator, Shionogi Inc., Pediatric Attention Deficit Hyperactivity Disorder, 155) Sub-investigator, Roche, Multiple Sclerosis, November 2011 156) Sub-investigator, Bristol-Myers Squibb, Migraines, November 2011 157) Sub-investigator, Pfizer, Sensorineural Hearing Loss, December 2011 158) Sub-investigator, Forest Laboratories, Major Depressive Disorder, December 2011

Source: http://www.psy.miami.edu/faculty/teaching/RRivas/cv_rrivas.pdf

Microsoft word - trad-pirofosfato.doc

PIROFOSFATO -Sn para marcaje con 99MTc Pyrophosphoric acid, tetrasodium-tin chloride salt product is fixed in only 60% of the cases. Fixation is not (PYROPHOSPATE) stable in the case of threat or anguish syndrome. Pharmacological category Pharmacokinetics Pyrophosphate - 99mTc accumulates selectively in the damaged myocardium and in imperfect osteogenic Composition

oftalmo.com

ARCH SOC ESP OFTALMOL 2007; 82: 521-522 SHORT COMMUNICATION ANISOCORIA RELATED TO BUPROPION IN MIGRAINE ANISOCORIA PRODUCIDA POR BUPROPIÓN EN PACIENTE MIGRAÑOSA VLEMING EN1, GUTIÉRREZ-ORTIZ C2, TEUS MA2 ABSTRACT Introduction: Bupropion is used to help people stop Introducción: El bupropión se usa como deshabi- smoking. This drug can cause visual alterations but,tuante

Copyright © 2010-2014 Pharmacy Pills Pdf